To include your compound in the COVID-19 Resource Center, submit it here.

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

How the Dutch Health Institute is using real-world data to assess the value of CAR Ts

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute is spearheading a new model that leverages real-world evidence extracted from electronic health records to conduct cost-effectiveness analyses.

“We are trying to get to the data ourselves,” said Amr Makady, senior policy advisor at The Dutch Health Institute (ZIN), a health technology assessment (HTA) body that provides reimbursement advice to the Ministry of Health in the Netherlands.

Makady said the agency has been “thinking about RWE for a long time

Read the full 1050 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE